Master Alliance Provisions Guide (MAPGuide)

Merck – MPP, Molnupiravir License Agreement

  • Term & termination | Effects of termination

MSD–MPP Agreement

6. Term And Termination

[…]

6.4 Effect of Termination. In the event that this Agreement is terminated other than under Sections 6.1 or 6.2 [Editor note: wrong reference, should be 6.2 and 6.3], all Sublicenses will be automatically be converted into direct licenses between MSD and the Sublicensees, provided Sublicensees are not in breach of the Sublicense. For the avoidance of doubt, if the termination of the Agreement results from Sections 6.1 and 6.2 [Editor note: wrong reference, should be 6.2 and 6.3], the Sublicenses will automatically be terminated.

[…]

6.7 Survival. Sections 2.10, 5.5, 6.4, 7, and 8 shall survive termination or expiry of this Agreement.

Form of Sublicense Agreement

10. Term And Termination

[…]

10.6 Conversion to Direct Licence with MSD. Subject always to the termination provisions of the MSD–MPP Agreement, in the event that the MSD–MPP Agreement is terminated prior to its Term, this Agreement shall be converted into a direct licence between MSD and Licensee, provided that Licensee is not in breach of this Agreement.

[…]

10.10 Rights on Termination. Any termination of this Agreement will not relieve Licensee of its obligations to pay any monies due or owing at the time of such termination and will not relieve any obligations, of either to the other Party, established prior to termination.

10.11 Survival. Sections 3A, 7.3, 8, 10.5, 11, and 12 shall survive termination or expiry of this Agreement.